Natalizumab and progressive multifocal leucoencephalopathy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17038473.
- Also identified by PMC identifier 1798374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.
Medical subject headings
- Antibodies, Monoclonal
- Leukoencephalopathy, Progressive Multifocal
- Opportunistic Infections